0.6978
                                            
            Bioatla Inc stock is traded at $0.6978, with a volume of 263.24K.
            It is down -0.81% in the last 24 hours and up +0.19% over the past month.
            BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
        
        See More
    Previous Close:
              $0.6948
            Open:
              $0.7068
            24h Volume:
                263.24K
            Relative Volume:
              0.27
            Market Cap:
                $40.73M
            Revenue:
              -
            Net Income/Loss:
              $-123.46M
            P/E Ratio:
              -0.2694
            EPS:
                -2.59
            Net Cash Flow:
                $-104.11M
            1W Performance:
              -9.32%
            1M Performance:
              +0.19%
            6M Performance:
                +41.75%
            1Y Performance:
              -64.10%
            Bioatla Inc Stock (BCAB) Company Profile
Name
                  
                      Bioatla Inc
                    
                Sector
                  Industry
                  Phone
                  
                      858-558-0708
                    
                Address
                  
                      11085 TORREYANA ROAD, SAN DIEGO
                    
                Compare BCAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS | 
|---|---|---|---|---|---|---|
|   
                          
                                BCAB
                            
                             Bioatla Inc | 0.6936 | 40.80M | 0 | -123.46M | -104.11M | -2.59 | 
|   
                          
                                VRTX
                            
                             Vertex Pharmaceuticals Inc | 425.60 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 | 
|   
                          
                                REGN
                            
                             Regeneron Pharmaceuticals Inc | 651.49 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 | 
|   
                          
                                ALNY
                            
                             Alnylam Pharmaceuticals Inc | 456.05 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 | 
|   
                          
                                ARGX
                            
                             Argen X Se Adr | 820.89 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 | 
|   
                          
                                INSM
                            
                             Insmed Inc | 189.47 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 | 
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change | 
|---|---|---|---|
| Aug-13-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform | 
| Nov-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral | 
| Sep-15-22 | Initiated | JMP Securities | Mkt Outperform | 
| May-05-22 | Downgrade | Credit Suisse | Outperform → Neutral | 
| Mar-21-22 | Initiated | H.C. Wainwright | Buy | 
| Oct-15-21 | Resumed | BTIG Research | Buy | 
| Jun-28-21 | Initiated | ROTH Capital | Buy | 
| May-05-21 | Resumed | Credit Suisse | Outperform | 
| Apr-26-21 | Resumed | Credit Suisse | Outperform | 
| Jan-11-21 | Initiated | BTIG Research | Buy | 
| Jan-11-21 | Initiated | Credit Suisse | Outperform | 
| Jan-11-21 | Initiated | JP Morgan | Overweight | 
| Jan-11-21 | Initiated | Jefferies | Buy | 
                    View All
                     
                  
                Bioatla Inc Stock (BCAB) Latest News
Is BioAtla Inc. a candidate for recovery play2025 Analyst Calls & Consistent Profit Trading Strategies - newser.com
Sentiment analysis tools applied to BioAtla Inc.2025 Trading Recap & Technical Entry and Exit Alerts - newser.com
Why BioAtla Inc. stock is favored by top institutions2025 Big Picture & Safe Capital Growth Trade Ideas - newser.com
Analyzing BioAtla Inc. with risk reward ratio chartsLayoff News & Verified Short-Term Plans - newser.com
Will BioAtla Inc. continue its uptrendQuarterly Profit Review & Consistent Income Trade Ideas - newser.com
How supply chain issues affect BioAtla Inc. stockAnalyst Upgrade & Weekly High Conviction Ideas - newser.com
Chart overlay techniques for tracking BioAtla Inc.Gold Moves & Low Drawdown Trading Strategies - newser.com
Measuring BioAtla Inc.’s beta against major indicesWeekly Trade Report & Weekly High Potential Stock Alerts - newser.com
What moving averages say about BioAtla Inc.2025 EndofYear Setup & Expert Verified Movement Alerts - newser.com
What to do if you’re stuck in BioAtla Inc.Weekly Trade Report & Weekly Breakout Stock Alerts - newser.com
Why BioAtla Inc. stock is a value investor pickWeekly Risk Summary & Advanced Technical Signal Analysis - Fundação Cultural do Pará
BioAtla’s Phase 1 Study on BA3182: A New Hope for Advanced Adenocarcinoma - TipRanks
Can BioAtla Inc. stock sustain institutional interest2025 Big Picture & Capital Protection Trade Alerts - Fundação Cultural do Pará
Bioatla Inc Stock (BCAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
        Open in Yahoo
        |
        Open in Google
            |
            Open in Finviz
        |
        Open in MarketWatch
            |
            Open in EDGAR    
        |
        Open in Reuters
    
    
                Cap:
                 
                  | 
                Volume (24h):
                 
            
         
                     
                             Get the Stockscreener App
                    Get the Stockscreener App